SYGNIS AG to receive €1.9 million non-dilutive R&D funding from the Spanish government
SYGNIS AG announced that the Spanish Ministry of Economy and Competitiveness (MINECO), Department of Research and Development, has granted two soft loans under its prestigious and very competitive RETOS program to fund DNA research projects undertaken by the Company in collaboration with the National Center for Molecular Biology, the San Carlos Hospital and the R&D foundation Juan Dominguez, all collaborators are based in Spain. Through RETOS the Spanish government is financing innovation and scientific research projects of high social and economic impact for small, medium-sized and larger enterprises by providing grants and interest-free or low-interest-rate soft loans with long-term durations.
The selection process of business projects for the RETOS program is very strict. The fact that SYGNIS was chosen amongst many candidates, validates the quality and high level of innovation in SYGNIS’ research and development activities.
The soft loans are granted for research and development activities undertaken by SYGNIS and its collaborators relating to SYGNIS’ TruePrime™ and PrimPol™ technologies and the development of a Cell-Free DNA kit. SYGNIS is entitled to receive up to €1.2 million over a period of three years. The loan duration is ten years and interest rate is 0.06%. There is a grace period in the first three years of the loan. Up to €0.75 million will be received by SYGNIS’ collaborators as government grants.
“This non-dilutive and affordable research and development financing of our core technologies by the Spanish government confirms our innovation strategy,” said Pilar de la Huerta, Co-CEO and CFO of SYGNIS AG. “SYGNIS is now part of the exclusive group of Companies that have received financing under the ambitious RETOS program of the Spanish government. We are proud to be announcing this important funding for our research projects. This funding verifies the quality of our projects, the high level of innovation and also the impact potential on society and the economy of SYGNIS’ technologies. This could be exceptional in the case of our Cell-Free DNA kit,” de la Huerta noted.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Science for the protection of consumers - BfR publishes its Annual Report for 2008

New biomarkers for coffee consumption

Laboratory equipment specialist KNAUER wanted to help save the world and now received German Innovation Award
Combining therapies appears safe, may benefit patients with advanced liver cancer, UF scientists say

The future of personalized cancer treatment: An entirely new direction for RNAi delivery

Proven for the First Time: The Microbiome of Fruit and Vegetables Positively Influences Diversity in the Gut - Bacterial diversity in the gut plays an important role in human health

Protein interactions: who is partying with whom and who is ruining the party? - New method for investigating protein interaction networks - also of interest for pharmaceutical research
Researchers identify phosphorylation process vital to cancer growth
Ebola virus disarmed by excising a single gene
A novel human stem cell-based model of ALS opens doors for rapid drug screening
